96 related articles for article (PubMed ID: 7607381)
21. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
22. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
23. [Effect of the proliferation rate on the course of node negative breast carcinoma].
Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
[TBL] [Abstract][Full Text] [Related]
24. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer.
Bhargava V; Thor A; Deng G; Ljung BM; Moore DH; Waldman F; Benz C; Goodson W; Mayall B; Chew K
Mod Pathol; 1994 Apr; 7(3):361-8. PubMed ID: 8058709
[TBL] [Abstract][Full Text] [Related]
25. [Special clinical and follow-up aspects of invasive lobular breast cancer].
Mitze M; Meyer F; Goepel E; Kleinkauf-Houcken A; Jonat W
Geburtshilfe Frauenheilkd; 1991 Dec; 51(12):973-9. PubMed ID: 1794684
[TBL] [Abstract][Full Text] [Related]
26. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
27. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
29. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
[TBL] [Abstract][Full Text] [Related]
30. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
31. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
32. [Clinical follow-up studies on the prognostic significance of immunohistochemical estrogen receptor determination of breast cancer].
Beck T; Finger C; Weikel W; Mitze M; Kreienberg R
Geburtshilfe Frauenheilkd; 1990 Dec; 50(12):935-40. PubMed ID: 2086335
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of triple negative in stage II/III breast cancer.
Elnashar AT; Ali el-SM; Gaber A
J Oncol Pharm Pract; 2012 Mar; 18(1):68-75. PubMed ID: 21422149
[TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemical detection of epidermal growth factor receptor (EGF-R) in paraffin sections of breast carcinoma tissue: correlation and clinical significance].
Beckmann MW; Tutschek B; Göhring UJ; Engels K; Picard FK; Scharl A; Niederacher D; Schnürch HG
Geburtshilfe Frauenheilkd; 1995 May; 55(5):258-65. PubMed ID: 7607382
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases.
Haerslev T; Jacobsen K; Nedergaard L; Zedeler K
Pathol Res Pract; 1994 Aug; 190(7):675-81. PubMed ID: 7808966
[TBL] [Abstract][Full Text] [Related]
36. [Clinical significance of tumor associated glycoprotein-72 expression in pPrimary breast carcinoma].
Wang SM; Mao J; Li B; Tang LL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Nov; 24(11):1084-6. PubMed ID: 18992198
[TBL] [Abstract][Full Text] [Related]
37. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
38. Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma.
Midulla C; Giovagnoli MR; Valli C; Vecchione A
Anal Quant Cytol Histol; 1995 Jun; 17(3):157-62. PubMed ID: 7546049
[TBL] [Abstract][Full Text] [Related]
39. [Expression of the p185neu oncoprotein indicates an unfavorable prognosis in small, node negative breast cancer without systemic adjuvant treatment (T1N0)].
Göhring UJ; Aslan-Schadwinkel Y; Scharl A
Geburtshilfe Frauenheilkd; 1993 Sep; 53(9):625-9. PubMed ID: 7901111
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.
Platt-Higgins AM; Renshaw CA; West CR; Winstanley JH; De Silva Rudland S; Barraclough R; Rudland PS
Int J Cancer; 2000 Mar; 89(2):198-208. PubMed ID: 10754500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
